Infused tumor-primed LNL T cells recognize the tumor-associated peptide presented on HLA class II via their native TCRs and directly lyse target cells through perforin/granzyme and/or Fas–FasL pathways, with cytokines (e.g., IFN-γ, TNF) aiding cytotoxicity.